(3Z)-3-(2-{5,5,8a-trimethyl-octahydro-1H-spiro[naphthalene-2,2'-oxirane]-1-yl}ethylidene)oxolan-2-one | 115753-79-2

• 物质功能分类: 天然产物 - 萜类
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酯类
• 英文名称: (3Z)-3-(2-{5,5,8a-trimethyl-octahydro-1H-spiro[naphthalene-2,2'-oxirane]-1-yl}ethylidene)oxolan-2-one
• 英文别名: (3Z)-3-[2-(5,5,8a-trimethylspiro[3,4,4a,6,7,8-hexahydro-1H-naphthalene-2,2'-oxirane]-1-yl)ethylidene]oxolan-2-one
• CAS: 115753-79-2
• 化学式: C₂₀H₃₀O₃
• 分子量: 318.4
• InChiKey: MBPTXJNHCBXMBP-RZNTYIFUSA-N

物化性质

• 沸点：
  459.6±28.0 °C(Predicted)
• 密度：
  1.10±0.1 g/cm3(Predicted)
• 溶解度：
  溶于氯仿、二氯甲烷、乙酸乙酯、DMSO、丙酮等。
• 物理描述：
  Solid
• 熔点：
  125.5-126°C

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.85
• 拓扑面积：
  38.8
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• [EN] INTRANASAL PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS<br/>[FR] COMPOSITIONS PHARMACEUTIQUES INTRANASALES D'INHIBITEURS DE CGRP
  申请人：BIOHAVEN PHARM HOLDING CO LTD

  公开号：WO2021127070A1

  公开（公告）日：2021-06-24

  Provided is pharmaceutical composition for intranasal delivery, wherein the pharmaceutical composition includes a therapeutically active ingredient including a CGRP inhibitor. Also provided is a method for delivering a CGRP inhibitor to a subject, wherein the method includes intranasally administering to the subject a composition including a therapeutically active component including a CGRP inhibitor.

  提供了一种用于鼻内给药的药物组合物，其中该药物组合物包括一种治疗有效成分，该治疗有效成分包括CGRP抑制剂。还提供了一种将CGRP抑制剂递送给主体的方法，该方法包括将包括治疗有效成分的药物组合物鼻内给药给主体，该治疗有效成分包括CGRP抑制剂。
• TWO-PHASE FERMENTATION PROCESS FOR THE PRODUCTION OF AN ORGANIC COMPOUND
  申请人：JANSSEN Antonius Cornelis Johannes Matheus

  公开号：US20160168595A1

  公开（公告）日：2016-06-16

  The invention relates to a two phase fermentation process for producing an organic compound, in particular an isoprenoid and to a bioreactor comprising a two phase fermentation system for producing an organic compound.

  本发明涉及一种用于生产有机化合物的两相发酵过程，特别是一种异戊二烯类化合物的生产方法，以及一种包括两相发酵系统的生物反应器，用于生产有机化合物。
• Novel formulations for treatment of migraine
  申请人：Zogenix, Inc.

  公开号：EP2756756A1

  公开（公告）日：2014-07-23

  Systems and methods are described for treating un-met medical needs in migraine and related conditions such as cluster headache. Included are treatments that are both rapid onset and long acting, which include sustained release formulations, and combination products, Also included are treatments for multiple symptoms of migraine, especially headache and nausea and vomiting. Systems that are self contained, portable, prefilled, and simple to self administer at the onset of a migraine attack are disclosed, and preferably include a needle-free injector and a high viscosity formulation, to eliminate such issues as fear of self administration with needles, and needle stick and cross contamination.

  描述了用于治疗偏头痛及相关疾病（如丛集性头痛）的未满足医疗需求的系统和方法。还包括治疗偏头痛的多种症状，特别是头痛、恶心和呕吐。已公开的系统具有自含式、便携式、预灌装和易于在偏头痛发作时自行给药等特点，最好包括无针注射器和高粘度配方，以消除对自行用针给药、针刺和交叉污染等问题的恐惧。
• GAS CHROMATOGRAPH AND SAMPLE INJECTION METHOD
  申请人：Shimadzu Corporation

  公开号：EP3370062A1

  公开（公告）日：2018-09-05

  A sample solution (21) that is a first solvent containing a sample is stored in a first storage section (17). A pseudo matrix solution (22) that is a second solvent, with higher polarity than the first solvent, in which a pseudo matrix is dissolved is stored in a second storage section (18). A suction control unit (191) causes the sample solution (21) in the first storage section (17) and the pseudo matrix solution (22) in the second storage section (18) to be sucked into a syringe (15). An injection control unit (192) causes the sample solution (21) and the pseudo matrix solution (22) to be vaporized in a sample vaporization chamber (12), by causing the sample solution (21) and the pseudo matrix solution (22) sucked into the syringe (15) to be injected into the sample vaporization chamber (12).

  样品溶液 (21) 是含有样品的第一种溶剂，储存在第一储存区 (17) 中。伪基质溶液（22）是第二种溶剂，极性高于第一种溶剂，溶解在其中的伪基质被储存在第二储存部分（18）中。抽吸控制单元 (191) 将第一储存区 (17) 中的样品溶液 (21) 和第二储存区 (18) 中的伪基质溶液 (22) 吸入注射器 (15) 中。注射控制单元 (192) 通过将吸入注射器 (15) 的样品溶液 (21) 和伪基质溶液 (22) 注射到样品汽化室 (12) 中，使样品溶液 (21) 和伪基质溶液 (22) 在样品汽化室 (12) 中汽化。
• NOVEL AIR PURIFICATION COMPOSITION HAVING ANTIVIRAL AND BACTERICIDAL FUNCTIONS
  申请人：Wang, Jingning

  公开号：EP3650105A1

  公开（公告）日：2020-05-13

  Disclosed is a novel air purification composition with antiviral and bactericidal functions, the composition at least comprising the following components in percentage by weight: 0.3%-1% of a black poplar essential oil, 0.1%-1% of a tea tree essential oil, 0.1%-0.5% of a Cupressus funebris essential oil, 0.1%-1% of an Artemisia apiacea essential oil, 0.1%-10% of a Sophora flavescens extract, 0. 1%-5% of a ginger extract, 5%-30% of a Cupressus funebris hydrolate, 0.5%-1% of a hyperbranched amino polymer, 0.5%-5% of a surfactant, and the balance being water.

  本发明公开了一种具有抗病毒和杀菌功能的新型空气净化组合物，该组合物按重量百分比至少包括以下成分：0.3%-1%的黑杨精油、0.1%-1%的茶树精油、0.1%-0.1%-5%的生姜提取物，5%-30%的冲天香水合物，0.5%-1%的超支化氨基酸聚合物，0.5%-5%的表面活性剂，余量为水。